Biosig Technologies, Inc. (NASDAQ:STEX – Get Free Report) Chairman Morgan Lee Lekstrom acquired 147,000 shares of the firm’s stock in a transaction dated Thursday, May 21st. The shares were purchased at an average cost of $1.04 per share, for a total transaction of $152,880.00. Following the completion of the acquisition, the chairman directly owned 269,500 shares in the company, valued at approximately $280,280. This represents a 120.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Morgan Lee Lekstrom also recently made the following trade(s):
- On Tuesday, April 14th, Morgan Lee Lekstrom sold 12,759 shares of Biosig Technologies stock. The shares were sold at an average price of $1.07, for a total value of $13,652.13.
Biosig Technologies Stock Performance
STEX stock opened at $1.28 on Friday. The firm has a fifty day simple moving average of $1.17. Biosig Technologies, Inc. has a fifty-two week low of $0.70 and a fifty-two week high of $14.11. The stock has a market capitalization of $231.86 million, a price-to-earnings ratio of -0.13 and a beta of 1.58.
Analyst Upgrades and Downgrades
STEX has been the subject of several recent analyst reports. Weiss Ratings upgraded Biosig Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 1st. Wall Street Zen lowered Biosig Technologies from a “hold” rating to a “strong sell” rating in a research note on Sunday, April 5th. Finally, Needham & Company LLC cut their price objective on Biosig Technologies from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $8.00.
Get Our Latest Stock Report on Biosig Technologies
About Biosig Technologies
Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.
Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.
Featured Articles
- Five stocks we like better than Biosig Technologies
- SpaceX IPO: Opportunity? Or the Ultimate Hype Trade?
- CAVA Group’s Stock Looks Delicious After Strong Earnings
- Lowe’s Finds Support at $215 After Q1 Earnings Sell-Off
- Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook
Receive News & Ratings for Biosig Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biosig Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
